Navigation Links
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
Date:11/16/2007

n prescribed to millions of patients worldwide. It is approved in 88 countries for the treatment of schizophrenia, in 77 countries for the treatment of bipolar mania, and in 11 countries including the U.S. for the treatment of bipolar depression. SEROQUEL XR was launched for the treatment of schizophrenia in the US in 2007, and clinical development programs and regulatory filings are planned for a number of other indications.

Important Safety Information for SEROQUEL and SEROQUEL XR

SEROQUEL XR is indicated for the acute and maintenance treatment of schizophrenia. SEROQUEL is indicated for the treatment of depressive episodes in bipolar disorder; acute manic episodes in bipolar I disorder, as either monotherapy or adjunct therapy to lithium or divalproex; and schizophrenia. Patients should be periodically reassessed to determine the need for treatment beyond the acute response.

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death, compared to placebo (4.5% vs 2.6%, respectively). SEROQUEL and SEROQUEL XR are not approved for the treatment of patients with dementia-related psychosis. (See Boxed Warning.)

Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies of major depressive disorder and other psychiatric disorders. Patients of all ages started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. SEROQUEL and SEROQUEL XR are not approved for use in patients under the age of 18 years. SEROQUEL XR is not approved for the treatment of depression, however SEROQUEL is approved for the treatment of bipolar depression. (See Boxed Warning.)

Hyperglycemia, in some cases extreme and associated with ketoacidosis,
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. CryoCor Receives FDA Approval for Right Atrial Flutter
8. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
9. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Zynerba Pharmaceuticals , Inc., a specialty pharmaceutical ... cannabinoid treatments, today announced that the company will present ... The conference will be held December 2 to 3, ... York . Zynerba,s Chairman and CEO, Armando ... December 2. To listen to a webcast ...
(Date:11/26/2014)... According to the new ... (Electric, Battery, Pneumatic), by Product (Drill, Saw, Stapler, ... Application (Orthopedic, ENT, Oral, Thoracic, Neurology) - Global ... Surgical Instruments Market is estimated to be worth ... is expected to grow at a moderate CAGR ...
(Date:11/26/2014)... , Nov. 25, 2014 ... focused on the development of mobile diagnostic ... testing in hospital and pre-hospital settings, today ... (ISO) 13485:2003 certification.  The certification was awarded ... of the world,s leading certification bodies. ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2
... Silence Therapeutics plc (AIM: SLN) ("Silence" or ... patent 7,893,245, titled "Interfering RNA Molecules," by the ... issued patent, which represents a continuation of previously ... RNAi molecules with defined positional modifications including siRNA ...
... Feb. 22, 2011 Covance Inc. (NYSE: CVD ... Annual Morningstar/NYSSA Healthcare Conference on Thursday, February 24, 2011 at ... the presentation at www.covance.com .  In order to register ... early. Covance, with headquarters in Princeton, New Jersey, ...
Cached Medicine Technology:Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 2Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 3Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 4Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference 2
(Date:11/27/2014)... The founders of VIM & VIGR, a company ... compression socks, are proud to announce the debut of their ... Pressure (TM) knitting technology that is designed to increase the ... to adding flair and style to a product that has ... eye of a writer at The New York Times ...
(Date:11/27/2014)... 27, 2014 VogueQueen.com is making every ... ladies across the world. As the premier online supplier ... is proud to release a huge selection of sexy ... outfits, it is also providing many beautiful styles in ... gowns at discounted prices. , “VogueQueen.com hopes to ...
(Date:11/27/2014)... This is a professional and ... For an overview analysis, the report introduces Insulin ... structure, industry overview, policy analysis, and news analysis, ... covers information on policy, plans for Insulin Market ... much more. , This report also ...
(Date:11/27/2014)... "The uglier, the better," says Dr. Kirk Kimmerling. "Every ... as we enjoy the ugly sweater contest." Last year's ... " It was a sight to see. She glued ... the Christmas balls were faces of the staff with Dr. ... this year, it's simple to get in on the fun. ...
(Date:11/27/2014)... 2014 VeloReality Inc. President Gary ... Life Videos (RLVs) of world-famous velo courses for the company's ... as other popular indoor velo trainers. Two dozen additional Real ... the end of November -- in time for the ... of rides in the VeloReality collection to over sixty. , ...
Breaking Medicine News(10 mins):Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 3
... Support will be held in Las Vegas, NV. LLE - Language ... non-English speaking customers in 150 languages. , ... Washington, D.C. (Vocus) March ... from across the world will gather in Las, Vegas Nevada at the ...
... is now the only over the counter treatment for,chronic and acute ... up the healing process and prevents scar formation. , ... ... is a novel product based on revolutionary technology in the healing ...
... nearly 30 years with Ridgecrest Regional Hospital, Chief Executive Officer David ... with a rich history of healthcare leadership in the state. Suver, ... February 17, has spent his entire healthcare leadership career in California. ... ...
... The popular television show "Extreme Makeover: Home Edition" ... Tucson girl diagnosed with a rare blood disorder who recently ... The program is scheduled to air on the ... (NYBC), whose divisions include Long Island Blood Services, New Jersey ...
... MedQuist Inc., (Nasdaq: MEDQ ) the largest ... announced its financial results for its full year and ... , Net revenues for the year ended December ... for the year ended December 31, 2007. The ...
... can strike younger adults , , WEDNESDAY, March 11 (HealthDay ... for quick diagnosis of a rare but potentially deadly ... death in young people. , The disease is arrhythmogenic ... causes the muscle cells of one of the heart,s ...
Cached Medicine News:Health News:LLE to Deliver Language Interpretation and Translation Solutions at Annual Customer Support Conference 2Health News:LLE to Deliver Language Interpretation and Translation Solutions at Annual Customer Support Conference 3Health News:Wound Be Gone: Quickly Gaining Strong Support from Clinician Experts in the Field of Wound Healing 2Health News:Ridgecrest Regional Hospital Hires New CEO 2Health News:Ridgecrest Regional Hospital Hires New CEO 3Health News:Why Blood and Bone Marrow Donors Are So Important: 'Extreme Makeover: Home Edition' Profiles Blood Drive Honoree Lizzie Bell 2Health News:Why Blood and Bone Marrow Donors Are So Important: 'Extreme Makeover: Home Edition' Profiles Blood Drive Honoree Lizzie Bell 3Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 2Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 3Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 4Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 5Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 6Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 7Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 8Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 9Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 10Health News:New Test Seems to Spot Deadly Heart Condition 2Health News:New Test Seems to Spot Deadly Heart Condition 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: